Postnatal depression ‐ not measured · women with gestational diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Induction of labour · women with gestational diabetes mellitus
Exercise showed no clear difference in induction of labour compared with control (low certainty).
1 finding from 1 review
Large‐for‐gestational age ‐ not reported · women with gestational diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Perinatal mortality · women with gestational diabetes mellitus
1 finding from 1 review
Recovery timea from second twitch (T2) to train‐of‐four ratio (TOFR) > 0.9 (moderate block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
1 finding from 1 review
Bradycardia · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
Sugammadex (any dose) probably leads to lower bradycardia compared with neostigmine (any dose) (moderate certainty).
1 finding from 1 review
Number of patients with postoperative nausea and vomiting (24 hours postoperatively) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
Sugammadex (any dose) may leads to lower PONV compared with neostigmine (any dose) (low certainty).
1 finding from 1 review
Overall signs of postoperative residual paralysis · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
Sugammadex (any dose) probably leads to lower overall signs of postoperative residual paralysis compared with neostigmine (any dose) (moderate certainty).
1 finding from 1 review
Risk of serious adverse eventsb · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
Sugammadex (any dose) showed no clear difference in risk of serious adverse eventsb compared with neostigmine (any dose) (low certainty).
1 finding from 1 review
Recovery timea from post‐tetanic count (PTC) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of adverse events and serious adverse eventsb, bradycardia, PONV, and signs of residual neuromuscular blockade · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recovery timea from second twitch (T2) to train‐of‐four ratio (TOFR) > 0.9 (moderate block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recovery timea from post‐tetanic count (PTC 1 to 5) to train‐of‐four ratio (TOFR) > 0.9 (deep block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
1 finding from 1 review
Risk of adverse events and serious adverse eventsb, bradycardia, PONV, and signs of residual neuromuscular blockade · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recovery timea from second twitch (T2) to train‐of‐four ratio (TOFR) > 0.9 (moderate block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recovery timea from post‐tetanic count (PTC) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of composite adverse eventsb · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
Sugammadex (any dose) probably leads to lower risk of composite adverse eventsb compared with neostigmine (any dose) (moderate certainty).
1 finding from 1 review
Freedom from atrial arrhythmia · people with non‐paroxysmal atrial fibrillation
Ablation may leads to higher freedom from atrial arrhythmia compared with antiarrhythmic drug (low certainty).
1 finding from 1 review
Participants needing cardioversion · people with non‐paroxysmal atrial fibrillation
Ablation probably leads to lower participants needing cardioversion compared with antiarrhythmic drug (moderate certainty).
1 finding from 1 review
Cardiac hospitalisation Hospitalisations directly related to ablation or antiarrhythmic drugs · people with non‐paroxysmal atrial fibrillation
Ablation may leads to lower cardiac hospitalisation Hospitalisations directly related to… compared with antiarrhythmic drug (low certainty).
1 finding from 1 review